2024-04-10 06:50:33 ET
Summary
- Halozyme's ENHANZE technology drives growth, with Q4 2023 revenue up 27% YoY, projecting $915-$985 million in 2024.
- Key revenue from royalties, notably Darzalex Faspro, with a healthy financial state highlighted by a strong current ratio and stock repurchasing.
- Future growth fueled by subcutaneous versions of blockbuster drugs like Opdivo, Ocrevus, and Vyvgart, despite some setbacks.
- Investment recommendation: Strong Buy, based on significant expansion potential, balanced by a note on high leverage and operational risks.
Introduction
Read the full article on Seeking Alpha
For further details see:
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics